default author photo

Rita Murri

Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases

Roma

Italy

SCHOLARLY PAPERS

2

DOWNLOADS

130

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

Sarilumab Use in Severe SARS-CoV-2 Pneumonia

Number of pages: 33 Posted: 23 Sep 2020
Catholic University of Milan - Fondazione Policlinico Universitario Agostino Gemelli, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Reumatologia, Catholic University of Rome, Catholic University of Milan - Fondazione Policlinico Universitario Agostino Gemelli, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Reumatologia, Catholic University of Rome - Center for Geriatric Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, iFondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Clinic Medica e Malattie Cardiovascolar, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze dell’Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Clinic Medica e Malattie Cardiovascolar, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Clinic Medica e Malattie Cardiovascolar, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Division of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Reumatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Reumatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Università Cattolica del Sacro Cuore, Divisione di Reumatologia, Università Cattolica del Sacro Cuore, Divisione di Reumatologia, Università Cattolica del Sacro Cuore, Divisione di Reumatologia, Università Cattolica del Sacro Cuore, Divisione di Reumatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCC, Division of Pulmonary Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCC, Division of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institute of Internal Medicine and Geriatrics, Catholic University of the Sacred Heart of Milan, Università Cattolica del Sacro Cuore di Milano, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Clinic Medica e Malattie Cardiovascolari, Catholic University of Milan - Pneumology Complex Operating Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS - Department of Anesthesia and Intensive Care Medicine, Catholic University of the Sacred Heart, Rome and Independent
Downloads 66 (907,769)
Citation 2

Abstract:

Loading...

Severe SARS-CoV-2 pneumonia; sarilumab; inflammation

2.

Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

Number of pages: 38 Posted: 05 Dec 2022
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Fondazione Policlinico Universitario A. Gemelli IRCCS - Section of Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, ASST Santi Paolo e Carlo, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Department of Systems Medicine, affiliation not provided to SSRN, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Sapienza University of Rome, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Rome Tor Vergata - Faculty of Medicine and Surgery, University of Rome Tor Vergata - Department of Systems Medicine, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, University of Milan - Clinic of Infectious Diseases and Tropical Medicine, Lazzaro Spallanzani National Institute for Infectious Diseases, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Lazzaro Spallanzani National Institute for Infectious Diseases - INMI, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Clinical Department and Independent
Downloads 64 (924,743)

Abstract:

Loading...

Interleukin-6 receptor inhibitors, Sarilumab, SARS-CoV-2 infection, Severe COVID-19 pneumonia, randomized clinical trial